Table 6 Incidence of treatment-related adverse reactions in the two groups
TACE + Sunitinib group(N = 47) | Sunitinib group(N = 51) | Comparison of AEs(All) | |||
|---|---|---|---|---|---|
AEs | AEs(Grade 3–4) | AEs | AEs(Grade 3–4) | Chi-square test (p-value) | |
Abdominal pain | 26(55.3%) | 1(2.1%) | 7(13.7%) | 0 | < 0.001 |
Fever | 29(61.7%) | 2(4.3%) | 4(7.8%) | 0 | < 0.001 |
Vomiting | 19(40.4%) | 0 | 10(19.6%) | 0 | 0.024 |
Asthenia | 27(57.4%) | 0 | 29(56.9%) | 1(2.0%) | 0.953 |
Decreased appetite | 21(44.7%) | 0 | 24(47.1%) | 1(2.0%) | 0.813 |
Hypertension | 18(38.3%) | 1(2.1%) | 16(31.4%) | 0 | 0.472 |
Hand-foot syndrome | 20(42.6%) | 0 | 21(41.2%) | 1(2.0%) | 0.890 |
Diarrhea | 14(29.8%) | 0 | 12(23.5%) | 0 | 0.483 |
Rash | 8(17.0%) | 0 | 6(11.8%) | 0 | 0.458 |